**EXPLANATORY STATEMENT**

*Therapeutic Goods Act 1989*

*Therapeutic Goods (Authorised Supply) Amendment (SAS Guidance) Rules 2024*

The *Therapeutic Goods Act 1989* (“the Act”) provides for the establishment and maintenance of a national system of controls for the quality, safety, efficacy or performance, and timely availability of therapeutic goods that are used in, or exported from, Australia. The Act is administered by the Therapeutic Goods Administration (“the TGA”) within the Australian Government Department of Health and Aged Care.

Subsections 19(7A), 32CM(7A) and 41HC(6) of the Act provide that the Minister may, by legislative instrument, make rules authorising specified classes of health practitioners to supply specified therapeutic goods, biologicals or kinds of medical devices (as relevant) for use in the treatment of specified recipients, provided the goods are supplied in specified circumstances and the specified conditions (if any) are satisfied.

These provisions are mainly intended to facilitate access to therapeutic goods with an established history of safe use in Australia or overseas, in circumstances where those goods are not included in the Australian Register of Therapeutic Goods (“the Register”), or not otherwise the subject of an exemption, approval or authority under the Act. Legislative instruments made under these provisions support what is known as the ‘Special Access Scheme – Category C pathway’.

The *Therapeutic Goods (Medicines and OTG—Authorised Supply) Rules 2022* (“the Medicines Rules”), the *Therapeutic Goods (Biologicals—Authorised Supply) Rules 2022* (“the Biologicals Rules”) and the *Therapeutic Goods (Medical Devices—Authorised Supply) Rules 2022* (“the Devices Rules”) are made under subsections 19(7A), 32CM(7A) and 41HC(6) of the Act, respectively. The Medicines Rules, Biologicals Rules and Devices Rules (collectively, “the Principal Rules”) specify health practitioners, therapeutic goods (medicines, biologicals and medical devices as relevant), circumstances and conditions.

The *Therapeutic Goods (Authorised Supply) Amendment (SAS Guidance) Rules 2024* (“the Amendment Rules”) amends the Principal Rules to update the definition of ‘SAS Guidance’ to refer to the updated guidance document titled *Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods* (Version 2.0, March 2024), as in force or existing on 1 April 2024 (“the SAS Guidance”). The Amendment Rules also amend the Medicines Rules to remove Gallium-68 prostate specific membrane antigen (PSMA), which has now been included on the Register, from Schedule 1 to the Medicines Rules.

**Background**

Subsection 19(7A) of the Act provides that the Minister may, by legislative instrument, make rules authorising specified classes of health practitioners to supply specified therapeutic goods (or classes of such goods) for use in the treatment of specified recipients, provided the goods are supplied in specified circumstances and the specified conditions (if any) are satisfied. Subsection 19(7B) of the Act provides that, in making rules under subsection 19(7A), the Minister must comply with such requirements, restrictions or limitations (if any) prescribed in the regulations. Subregulation 12B(5) of the *Therapeutic Goods Regulations 1990* provides that rules made under subsection 19(7A) of the Act must not specify a medicine or a class of medicines if the medicine, or a medicine included in the class, contains a substance of a kind covered by an entry in Schedule 8, 9, or 10 to the Poisons Standard. Health practitioners who supply therapeutic goods pursuant to rules made under subsection 19(7A) are also required to notify the Secretary in accordance with subsections 19(7C) and 19(7D) of the Act.

The SAS Category C pathway is a notification pathway, allowing specified health practitioners to supply certain specified unapproved therapeutic goods that are considered by the TGA to have an established history of safe use. The TGA periodically reviews the unapproved therapeutic goods accessed through the various SAS pathways to determine if any amendments are required to the instruments, including the removal of products due to product inclusion on the Register or safety risks.

Similarly, subsection 32CM(7A) of the Act provides that the Minister may, by legislative instrument, make rules authorising any health practitioner who is included in a specific class of health practitioners to supply a specified biological, for use in the treatment of humans, to the class or classes of recipients specified in the rules, so long as the biological is supplied in the circumstances specified in those rules and the conditions (if any) specified in those rules are satisfied. Subsection 32CM(7B) of the Act provides that, in making rules under subsection 32CM(7A), the Minister must comply with such requirements, restrictions or limitations (if any) prescribed in the regulations. No regulations have been made for the purposes of subsection 32CM(7B). Health practitioners who supply therapeutic goods pursuant to rules made under subsection 32CM(7A) are also required to notify the Secretary in accordance with subsections 32CM(7C) and 32CM(7D) of the Act.

Subsection 41HC(6) of the Act provides that the Minister may, by legislative instrument, make rules authorising specified classes of health practitioners to supply a specified kind of medical device for use in the treatment of specified recipients, provided the kinds of medical devices are supplied in specified circumstances and the specified conditions (if any) are satisfied. Subsection 41HC(6A) of the Act provides that, in making rules under subsection 41HC(6), the Minister must comply with such requirements, restrictions or limitations (if any) prescribed in the regulations. No regulations have been made for the purposes of subsection 41HC(6A). Health practitioners who supply kinds of medical devices pursuant to rules made under subsection 41HC(6) of the Act are also required to notify the Secretary in accordance with subsections 41HC(6B) and 41HC(6C) of the Act.

**Purpose**

The Medicines Rules, the Biologicals Rules and the Devices Rules are made under subsections 19(7A), 32CM(7A) and 41HC(6) of the Act, respectively. The Principal Rules specify conditions that must be satisfied which include conditions relating to notifying the TGA and the sponsor about an adverse event a patient has suffered in relation to the therapeutic good, and notifying the TGA and the sponsor of a defect in the therapeutic goods. The notification must be in accordance with the reporting guidelines set out in the SAS Guidance.

The SAS Guidance is published by the TGA to assist health practitioners understand their requirements when prescribing ‘unapproved’ therapeutic goods for an individual patient using the Special Access Scheme. As the SAS Guidance published by the TGA was updated in March 2024, the Amendment Rules make amendments necessary to ensure that health practitioners access the correct guidance document to understand their requirements when prescribing ‘unapproved’ therapeutic goods using the Special Access Scheme and notifying the TGA of adverse events or defects.

The updates to the SAS Guidance made in March 2024 are limited to removing references to paper-based submissions under the SAS Category A, B and C pathways; and the Authorised Prescriber Scheme.

Gallium-68 PSMA is currently included in Schedule 1 to the Medicines Rules as it has an established history of safe use and it is primarily accessed through the SAS C notification pathway. On 10 November 2021, ILLUCCIX® was included on the Register (ARTG ID: 356332 and 356333) and therefore may be lawfully supplied in Australia. The Amendment Rules amends the Medicines Rules to remove Gallium-68 PSMA from Schedule 1 of the Medicines Rules as access through the SAS C pathway is no longer necessary.

**Incorporation by reference**

The Amendment Rules incorporate by reference the document titled *Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods* (Version 2.0, March 2024), which is published by the TGA. This document provides guidance for health practitioners and sponsors involved in providing patients with access to therapeutic goods that are not included in the Register (and are not otherwise the subject of an exemption, approval or authority under the Act) through the Special Access Scheme. It outlines the various access pathways and the regulatory obligations when accessing and supplying such therapeutic goods.

The Amendment Rules incorporate the SAS Guidance as in force or existing on 1 April 2024, in accordance with paragraph 14(1)(b) of the *Legislation Act* *2003*, which permits a legislative instrument to incorporate a document (that is not an Act or legislative instrument) as it exists at, or before, the time the instrument commences. The SAS Guidance is available for free from the TGA website and may be accessed at www.tga.gov.au.

**Consultation**

In July 2018, the TGA launched its online system for SAS applications and notifications. Since then, the TGA has encouraged health practitioners to use the online system, which offers greater oversight of submissions and faster approval timeframes. The online system has also been enhanced to improve reliability and the user experience.

On 29 February 2024, a communique was released on the TGA website which announced the TGA’s plan to transition to a paperless model for SAS and AP submissions from 1 July 2024. The communique was also emailed directly to all health practitioners who access unapproved therapeutic goods, was announced on the TGA’s LinkedIn social posts for health practitioners, was announced in the ‘On the Radar’ publication by the Australian Commission on Safety and Quality in Health Care and was advertised in the TGA Health Professional update. The communique provided stakeholders with an email address for questions or comments on the proposed transition. The TGA received a small number of responses to the communique, and are working closely with these health practitioners to address their concerns. The TGA also directly contacted health practitioners that are known to submit a high-volume of paper applications/notifications to assist in their transition to using the online system. Whilst most stakeholders did raised concerns in relation to the transition to using the online system, the TGA is continuing to work closely with some health practitioners to assist them with the transition.

Consultation on the removal of Gallium-68 PSMA from the Medicines Rules was not undertaken due to it being a minor and machinery amendment resulting from that medicine being available for general supply in Australia (having been evaluated for quality, safety and efficacy) and no longer needing to be accessed through the SAS C pathway.

The Office of Impact Analysis advised that an impact analysis was not required in relation to amendment to the Principal Rules to refer to the updated SAS guidance, as the proposal relates to minor changes to reference an updated guide rather than a substantive policy change (OIA24-07497). The Office of Impact Analysis also advised that an impact analysis was not required in relation to the removal of Gallium-68 PSMA from the Medicines Rules as the proposal is unlikely to have more than a minor regulatory impact (OIA23-04757).

**Other details**

Details of the Amendment Rules are set out in **Attachment A**.

The Amendment Rules are compatible with human rights and freedoms recognised or declared under section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*. A full statement of compatibility is set out in **Attachment B**.

The Amendment Rules are a disallowable legislative instrument for the purposes of the *Legislation Act 2003*,and commence on the day following registration on the Federal Register of Legislation.

**Attachment A**

**Details of the *Therapeutic Goods (Authorised Supply) Amendment (SAS Guidance) Rules 2024***

**Section 1 – Name**

This section provides that the name of the instrument is the *Therapeutic Goods (Authorised Supply) Amendment (SAS Guidance) Rules 2024* (“the Amendment Rules”).

**Section 2 – Commencement**

This section provides that the Amendment Rules commence on the day after they are registered on the Federal Register of Legislation.

**Section 3 – Authority**

This section provides that the legislative authority for making the Amendment Rules is subsections 19(7A), 32CM(7A) and 41HC(6) of the *Therapeutic Goods Act 1989* (“the Act”).

Subsection 33(3) of the *Acts Interpretation Act 1901* relevantly provides that, where an Act confers a power to make, grant or issue any instrument of a legislative or administrative character, the power shall be construed as including a power exercisable in the like manner and subject to the like conditions (if any) to repeal, rescind, revoke, amend, or vary any such instrument. The Amendment Rules are made in accordance with that provision.

**Section 4 – Schedules**

This section gives legal effect to the amendments in Schedule 1 to the Amendment Rules.

**Schedule 1 – Amendments**

This Schedule amends the *Therapeutic Goods (Medicines and OTG—Authorised Supply) Rules 2022* (“the Medicines Rules”), the *Therapeutic Goods (Biologicals—Authorised Supply) Rules 2022* (“the Biologicals Rules”) and the *Therapeutic Goods (Medical Devices—Authorised Supply) Rules 2022* (“the Devices Rules”).

Item 1 replaces the definition of ‘SAS Guidance’ in section 4 of the Biologicals Rules to reflect that ‘SAS Guidance’ means the updated guidance titled *Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods* (Version 2.0, March 2024), as in force or existing on 1 April 2024.

Item 2 replaces the definition of ‘SAS Guidance’ in section 4 of the Devices Rules to reflect that ‘SAS Guidance’ means the updated guidance titled *Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods* (Version 2.0, March 2024), as in force or existing on 1 April 2024.

Item 3 replaces the definition of ‘SAS Guidance’ in section 4 of the Medicines Rules to reflect that ‘SAS Guidance’ means the updated guidance titled *Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods* (Version 2.0, March 2024), as in force or existing on 1 April 2024.

Item 4 removes table item 36, Gallium-68 prostate specific membrane antigen, from Schedule 1 of the Medicines Rules as it was included in the ARTG (ARTG ID: 356332 and 356333).

**Attachment B**

**Statement of Compatibility with Human Rights**

Prepared in accordance with Part 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

***Therapeutic Goods (Authorised Supply) Amendment (SAS Guidance) Rules 2024***

This disallowable legislative instrument is compatible with the human rights and freedoms recognised or declared in the international instruments listed in section 3 of the *Human Rights (Parliamentary Scrutiny) Act 2011*.

**Overview of legislative instrument**

Subsections 19(7A), 32CM(7A) and 41HC(6) of the *Therapeutic Goods Act 1989* (“the Act”) provide that the Minister may, by legislative instrument, make rules authorising specified classes of health practitioners to supply specified therapeutic goods, biologicals or kinds of medical devices (as relevant) for use in the treatment of specified recipients, provided the goods are supplied in specified circumstances and the specified conditions (if any) are satisfied.

These provisions are mainly intended to facilitate access to therapeutic goods with an established history of safe use in Australia or overseas, in circumstances where those goods are not included in the Australian Register of Therapeutic Goods (“the Register”), or not otherwise the subject of an exemption, approval or authority under the Act. Legislative instruments made under these provisions support what is known as the ‘Special Access Scheme – Category C pathway’.

The *Therapeutic Goods (Medicines and OTG—Authorised Supply) Rules 2022* (“the Medicines Rules”), the *Therapeutic Goods (Biologicals—Authorised Supply) Rules 2022* (“the Biologicals Rules”) and the *Therapeutic Goods (Medical Devices—Authorised Supply) Rules 2022* (“the Devices Rules”) are made under subsections 19(7A), 32CM(7A) and 41HC(6) of the Act, respectively. The Medicines Rules, Biologicals Rules and Devices Rules (collectively, “the Principal Rules”) specify health practitioners, therapeutic goods (medicines, biologicals and medical devices as relevant), circumstances and conditions.

The *Therapeutic Goods (Authorised Supply) Amendment (SAS Guidance) Rules 2024* (“the Amendment Rules”) amends the Principal Rules to update the definition of ‘SAS Guidance’ to refer to the updated guidance document titled *Special Access Scheme (SAS): Guidance for health practitioners accessing unapproved therapeutic goods* (Version 2.0, March 2024), as in force or existing on 1 April 2024 (“the SAS Guidance”). The Amendment Rules also amend the Medicines Rules to remove Gallium-68 prostate specific membrane antigen (PSMA), which has now been included on the Register, from Schedule 1 to the Medicines Rules.

*Background*

Subsection 19(7A) of the Act provides that the Minister may, by legislative instrument, make rules authorising specified classes of health practitioners to supply specified therapeutic goods (or classes of such goods) for use in the treatment of specified recipients, provided the goods are supplied in specified circumstances and the specified conditions (if any) are satisfied. Subsection 19(7B) of the Act provides that, in making rules under subsection 19(7A), the Minister must comply with such requirements, restrictions or limitations (if any) prescribed in the regulations. Subregulation 12B(5) of the *Therapeutic Goods Regulations 1990* provides that rules made under subsection 19(7A) of the Act must not specify a medicine or a class of medicines if the medicine, or a medicine included in the class, contains a substance of a kind covered by an entry in Schedule 8, 9, or 10 to the Poisons Standard. Health practitioners who supply therapeutic goods pursuant to rules made under subsection 19(7A) are also required to notify the Secretary in accordance with subsections 19(7C) and 19(7D) of the Act.

The SAS Category C pathway is a notification pathway, allowing specified health practitioners to supply certain specified unapproved therapeutic goods that are considered by the TGA to have an established history of safe use. The TGA periodically reviews the unapproved therapeutic goods accessed through the various SAS pathways to determine if any amendments are required to the instruments, including the removal of products due to product inclusion on the Register or safety risks.

Similarly, subsection 32CM(7A) of the Act provides that the Minister may, by legislative instrument, make rules authorising any health practitioner who is included in a specific class of health practitioners to supply a specified biological, for use in the treatment of humans, to the class or classes of recipients specified in the rules, so long as the biological is supplied in the circumstances specified in those rules and the conditions (if any) specified in those rules are satisfied. Subsection 32CM(7B) of the Act provides that, in making rules under subsection 32CM(7A), the Minister must comply with such requirements, restrictions or limitations (if any) prescribed in the regulations. No regulations have been made for the purposes of subsection 32CM(7B). Health practitioners who supply therapeutic goods pursuant to rules made under subsection 32CM(7A) are also required to notify the Secretary in accordance with subsections 32CM(7C) and 32CM(7D) of the Act.

Subsection 41HC(6) of the Act provides that the Minister may, by legislative instrument, make rules authorising specified classes of health practitioners to supply a specified kind of medical device for use in the treatment of specified recipients, provided the kinds of medical devices are supplied in specified circumstances and the specified conditions (if any) are satisfied. Subsection 41HC(6A) of the Act provides that, in making rules under subsection 41HC(6), the Minister must comply with such requirements, restrictions or limitations (if any) prescribed in the regulations. No regulations have been made for the purposes of subsection 41HC(6A). Health practitioners who supply kinds of medical devices pursuant to rules made under subsection 41HC(6) of the Act are also required to notify the Secretary in accordance with subsections 41HC(6B) and 41HC(6C) of the Act.

*Purpose*

The Medicines Rules, the Biologicals Rules and the Devices Rules are made under subsections 19(7A), 32CM(7A) and 41HC(6) of the Act, respectively. The Principal Rules specify conditions that must be satisfied which include conditions relating to notifying the TGA and the sponsor about an adverse event a patient has suffered in relation to the therapeutic good, and notifying the TGA and the sponsor of a defect in the therapeutic goods. The notification must be in accordance with the reporting guidelines set out in the SAS Guidance.

The SAS Guidance is published by the TGA to assist health practitioners understand their requirements when prescribing ‘unapproved’ therapeutic goods for an individual patient using the Special Access Scheme. As the SAS Guidance published by the TGA was updated in March 2024, the Amendment Rules make amendments necessary to ensure that health practitioners access the correct guidance document to understand their requirements when prescribing ‘unapproved’ therapeutic goods using the Special Access Scheme and notifying the TGA of adverse events or defects.

The updates to the SAS Guidance made in March 2024 are limited to removing references to paper-based submissions under the SAS Category A, B and C pathways; and the Authorised Prescriber Scheme.

Gallium-68 PSMA is currently included in Schedule 1 to the Medicines Rules as it has an established history of safe use and it is primarily accessed through the SAS C notification pathway. On 10 November 2021, ILLUCCIX® was included on the Register (ARTG ID: 356332 and 356333) and therefore may be lawfully supplied in Australia. The Amendment Rules amends the Medicines Rules to remove Gallium-68 PSMA from Schedule 1 of the Medicines Rules as access through the SAS C pathway is no longer necessary.

**Human rights implications**

The Amendment Rules engage the right to health in Article 12 of the International Covenant on Economic, Social and Cultural Rights (“the ICESCR”).Article 12 of the ICESCR promotes the right of all individuals to enjoy the highest attainable standards of physical and mental health, and includes an obligation to take reasonable measures within available resources to progressively secure broader enjoyment of the right.

In *General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art. 12)* (2000), the United Nations Committee on Economic, Social and Cultural Rights states that health is a ‘fundamental human right indispensable for the exercise of other human rights’, and that the right to health is not to be understood as the right to be healthy, but includes the right to a system of health protection which provides equal opportunity for people to enjoy the highest attainable level of health.

The Amendment Rules support the right to health by ensuring the Principal Rules include an up-to-date reference to the SAS Guidance, and that any adverse events in relation to therapeutic goods or defects in the therapeutic goods are reported to the TGA (and sponsor of the goods) in accordance with the reporting guidelines set out in the latest version of the SAS Guidance. The requirement in the Principal Rules to notify the TGA of adverse events or defects enables the TGA to investigate safety signals and take necessary action to protect patients from any safety concerns identified and prevent further harm/injury.

**Conclusion**

This instrument is compatible with human rights because it supports the right to health in Article 12 of the ICESCR and otherwise does not raise any other human rights issues.